Loading
Life sciences · Journal article
Holistic Integrative Oncology · October 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Despite revolutionary advances in immunotherapy and targeted therapies, tumor recurrence driven by minimal residual disease (MRD) and drug-tolerant persister (DTP) cells remains a critical challenge in oncology. MRD, a reservoir of residual cancer cells undetectable by conventional imaging but identifiable via sensitive molecular techniques like next-generation sequencing and ctDNA analysis, serves as a prognostic biomarker for relapse across hematologic and solid malignancies. Within MRD, DTP cells, characterized by transient drug tolerance, evade therapies through adaptive mechanisms such as quiescence, metabolic reprogramming, epigenetic modifications, and signaling pathway activation. These cells, pivotal in mediating therapeutic resistance, dynamically evolve from reversible tolerance to stable resistance, fueling disease relapse. This review elucidates the clinical significance of MRD and DTP cells, detailing their biological characteristics, detection technologies, and formation mechanisms. We highlight therapeutic strategies targeting DTP cells, including pathway inhibitors, epigenetic modulators, and autophagy blockers, to reverse MRD and prevent recurrence. Challenges in translating these approaches to clinical practice, such as DTP heterogeneity and biomarker development, are addressed alongside emerging technologies like single-cell omics and AI-driven analytics. By integrating mechanistic insights with innovative detection and therapeutic strategies, targeting DTP cells within MRD holds transformative potential to enhance long-term cancer outcomes.